HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pollard, A J Articles by Moxon, E R Search for Related Content PubMed PubMed Citation Articles by Pollard, A J Articles by Moxon, E R Topic Collections Relevant Article

The meningococcus tamed?

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK

Correspondence to:
Correspondence to:
Dr A J Pollard, Oxford Vaccine Group, Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK;
andrew.pollard{at}paediatrics.ox.ac.uk

ABSTRACT
Serogroup B Neisseria meningitidis is a frequent cause of invasive meningococcal disease, yet there are no effective vaccines suitable for routine immunisation. Limited efficacy has been shown with meningococcal outer membrane vacccines in children 4 years and older. Here we review the status of current research and consider new approaches to development of meningococcal serogroup B vaccines.

Keywords: meningococcus; vaccine; meningitis; review; immunisation

Abbreviations: Hib, Haemophilus influenzae type b; LPS, lipopolysaccharide; OMP, outer membrane protein; OMV, outer membrane vesicle

Relevant Article

KEEPING IT CLEAN

Harvey Marcovitch
Arch. Dis. Child. 2002 87: 1. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				C. Sorhouet Pereira, M. Regueira, and M. Mollerach PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: implications for the design of an outer membrane protein-based vaccine J. Med. Microbiol., March 1, 2008; 57(3): 338 - 342. [Abstract] [Full Text] [PDF]

				M. El Khattabi, H. Adams, E. Heezius, P. Hermans, F. Detmers, B. Maassen, P. van der Ley, J. Tommassen, T. Verrips, and J. Stam Llama Single-Chain Antibody That Blocks Lipopolysaccharide Binding and Signaling: Prospects for Therapeutic Applications Clin. Vaccine Immunol., October 1, 2006; 13(10): 1079 - 1086. [Abstract] [Full Text] [PDF]

				R S Heyderman, Y Ben-Shlomo, C A Brennan, and M Somerset The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics Arch. Dis. Child., November 1, 2004; 89(11): 1064 - 1068. [Abstract] [Full Text] [PDF]

				M. A. J. Gidney, J. S. Plested, S. Lacelle, P. A. Coull, J. C. Wright, K. Makepeace, J.-R. Brisson, A. D. Cox, E. R. Moxon, and J. C. Richards Development, Characterization, and Functional Activity of a Panel of Specific Monoclonal Antibodies to Inner Core Lipopolysaccharide Epitopes in Neisseria meningitidis Infect. Immun., January 1, 2004; 72(1): 559 - 569. [Abstract] [Full Text] [PDF]

				S B Welch and S Nadel Treatment of meningococcal infection Arch. Dis. Child., July 1, 2003; 88(7): 608 - 614. [Abstract] [Full Text] [PDF]